EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice

Maria Choví-Trull, Juan Eduardo Megías-Vericat, Santiago Bonanad Boix, Saturnino Haya Guaita, Ana Rosa Cid Haro, Marta Aguilar Rodriguez, Jose Luis Poveda Andrés

Farmacia Hospitalaria · 2025

DOI: 10.1016/j.farma.2024.12.007 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Farmacia Hospitalaria, 2025. Verfasst von Maria Choví-Trull und 6 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Farmacia, Hospital Universitari i Politècnic La Fe, Valencia, Spain. Electronic address: mariach22ch@gmail.com. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: McMaster University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To analyse the differences in pharmacokinetic and clinical parameters (bleeding rates and joint health) before and after switching from standard half-life factor VIII (FVIII) to extended half-life pegylated FVIII in patients with severe/moderate haemophilia A on prophylaxis, 1 year before and after the switch in real-life. METHOD: This is a single-centre, comparative, observational, sequential, retrospective, and multidisciplinary study. Population pharmacokinetic models from the WAPPS-Hemo® application were used to calculate pharmacokinetic parameters and individualise prophylaxis. The annual rate of total and joint bleeds, joint health (Haemophilia Joint Health Score), plasma half-life and area under the curve ratios, FVIII consumption, administration frequency, and cost were analysed. RESULTS: Thirty-eight adult patients with haemophilia A who switched from standard half-life FVIII to extended half-life pegylated FVIII were analysed. Significant improvements (P < .05) were observed in all pharmacokinetic parameters, with plasma half-life and area under the curve improvement ratios of 1.5 and 1.9, respectively, as well as reductions in annual total and joint bleeding rates. A higher number of patients with zero total (16.0 vs. 29.0) and joint bleeds (23.0 vs. 33.0) was also observed. The median reductions in administration frequency and dose/kg/week were 30.0% and 19.7%, respectively, avoiding 44.3 infusions/patient/year, resulting in savings of 20,843 €/patient/year. Furthermore, joint health improved (23.0 vs. 21.0; P = .017), and target joints resolved after the switch. CONCLUSIONS: The pharmacokinetically guided switch from standard half-life FVIII to pegylated FVIII demonstrated significant clinical benefits with reduced bleeding rates and improvements in joint health. Additionally, improvements in pharmacokinetic parameters were observed, allowing for reduced treatment burden by decreasing administration frequency, as well as lower consumption and costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIHumansHalf-LifeRetrospective StudiesAdultMaleMiddle AgedPolyethylene GlycolsHemorrhageYoung AdultFemaleAged

Stichwörter der Autor:innen

Damoctocog alfa pegolFactor VIIIHaemophilia AHalf-lifeHemofilia APharmacokineticsPolyethylene glycolsRurioctocog alfa pegolTuroctocog alfa pegoldamoctocog alfa pegolfactor VIIIfarmacocinéticapolietilenglicolesrurioctocog alfa pegolsemivida plasmática

Substanzen

Factor VIIIPolyethylene Glycols

Autor:innen und Institutionen

  • Servicio de Farmacia, Hospital Universitari i Politècnic La Fe, Valencia, Spain. Electronic address: mariach22ch@gmail.com.
  • Servicio de Farmacia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Unidad de Hemostasia y Trombosis, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Unidad de Hemostasia y Trombosis, Hospital Universitari i Politècnic La Fe, Valencia, Spain; Fisioterapia en movimiento, Grupo de investigación multiespecialidad (PTinMOTION), Universitat de Fisioterapia de València, Va…
  • Gerencia Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Förderung

  • McMaster University

Zitieren

APA

Choví-Trull, M., Megías-Vericat, J. E., Bonanad Boix, S., Haya Guaita, S., Cid Haro, A. R., Aguilar Rodriguez, M., & Poveda Andrés, J. L. (2025). [Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2024.12.007

Vancouver

Choví-Trull M, Megías-Vericat JE, Bonanad Boix S, Haya Guaita S, Cid Haro AR, Aguilar Rodriguez M, et al. [Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice. Farmacia Hospitalaria. 2025. doi:10.1016/j.farma.2024.12.007

BibTeX
@article{ChovTrull2025,
  author = {Choví-Trull, Maria and Megías-Vericat, Juan Eduardo and Bonanad Boix, Santiago and Haya Guaita, Saturnino and Cid Haro, Ana Rosa and Aguilar Rodriguez, Marta and Poveda Andrés, Jose Luis},
  title = {[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice},
  journal = {Farmacia Hospitalaria},
  year = {2025},
  doi = {10.1016/j.farma.2024.12.007}
}
Kostenlos starten →